Crossmark

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma

Crossref DOI link: https://doi.org/10.1186/s13046-018-0723-5

Published Online: 2018-03-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Thomsen, C. B. https://orcid.org/0000-0003-4481-6274
Hansen, T. F.

Andersen, R. F.

Lindebjerg, J.

Jensen, L. H.

Jakobsen, A.
License Information

Text and Data Mining valid from 2018-03-12
More Information

Article History

Received: 12 December 2017

Accepted: 27 February 2018

First Online: 12 March 2018

Ethics approval and consent to participate

: All patients gave oral and written consent to participate in the study. The study was approved by The Regional Committees on Health Research Ethics for Southern Denmark (S-20100005) and the investigation was conducted in accordance with the REMARK criteria [].

: Not applicable.

: The authors have declared no conflicts of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.